A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China
<p>Abstract</p> <p>Background and purpose</p> <p>The response to remission induction in elderly patients with acute myeloid leukemia (AML) remains poor. The purpose of this paper is to evaluate the efficacy and toxicity of a plant alkaloid, homoharringtonine, in combina...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-07-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | http://www.jhoonline.org/content/2/1/32 |
| _version_ | 1818531575889920000 |
|---|---|
| author | Huang Chongmei Chen Li Song Xianmin Yang Jianmin Lü Shuqing Wang Jianmin Hou Jun Zhang Weiping |
| author_facet | Huang Chongmei Chen Li Song Xianmin Yang Jianmin Lü Shuqing Wang Jianmin Hou Jun Zhang Weiping |
| author_sort | Huang Chongmei |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background and purpose</p> <p>The response to remission induction in elderly patients with acute myeloid leukemia (AML) remains poor. The purpose of this paper is to evaluate the efficacy and toxicity of a plant alkaloid, homoharringtonine, in combination with cytarabine as an induction therapy for AML in elderly patients (≥60 years).</p> <p>Results</p> <p>Twenty-three patients were treated with the HA regimen consisting of homoharringtonine (2 mg/m<sup>2</sup>/day for 7 days) and cytarabine (Ara-C, 100 mg/m<sup>2</sup>/day for 7 days). The overall response rate was 56.5% with complete remission (CR) rate of 39.1% and partial remission of 17.4%. There was no early death in this cohort of patients. The estimated median overall survival (OS) time of all patients was (12.0 ± 3.0) months. The estimated OS time of the CR patients was 15 months. The estimated one-year OS rate of all patients treated with HA protocol was (49.3 ± 13.5) %. The estimated one-year OS rate of the CR patients was (62.5 ± 17.1) %.</p> <p>Conclusion</p> <p>HA is a suitable induction regimen for elderly patients with AML, with relatively low toxicity and reasonable response rate.</p> |
| first_indexed | 2024-12-11T17:34:15Z |
| format | Article |
| id | doaj.art-d8e9a637dac84950a122c90e52f792b6 |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-12-11T17:34:15Z |
| publishDate | 2009-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-d8e9a637dac84950a122c90e52f792b62022-12-22T00:56:44ZengBMCJournal of Hematology & Oncology1756-87222009-07-01213210.1186/1756-8722-2-32A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from ChinaHuang ChongmeiChen LiSong XianminYang JianminLü ShuqingWang JianminHou JunZhang Weiping<p>Abstract</p> <p>Background and purpose</p> <p>The response to remission induction in elderly patients with acute myeloid leukemia (AML) remains poor. The purpose of this paper is to evaluate the efficacy and toxicity of a plant alkaloid, homoharringtonine, in combination with cytarabine as an induction therapy for AML in elderly patients (≥60 years).</p> <p>Results</p> <p>Twenty-three patients were treated with the HA regimen consisting of homoharringtonine (2 mg/m<sup>2</sup>/day for 7 days) and cytarabine (Ara-C, 100 mg/m<sup>2</sup>/day for 7 days). The overall response rate was 56.5% with complete remission (CR) rate of 39.1% and partial remission of 17.4%. There was no early death in this cohort of patients. The estimated median overall survival (OS) time of all patients was (12.0 ± 3.0) months. The estimated OS time of the CR patients was 15 months. The estimated one-year OS rate of all patients treated with HA protocol was (49.3 ± 13.5) %. The estimated one-year OS rate of the CR patients was (62.5 ± 17.1) %.</p> <p>Conclusion</p> <p>HA is a suitable induction regimen for elderly patients with AML, with relatively low toxicity and reasonable response rate.</p>http://www.jhoonline.org/content/2/1/32 |
| spellingShingle | Huang Chongmei Chen Li Song Xianmin Yang Jianmin Lü Shuqing Wang Jianmin Hou Jun Zhang Weiping A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China Journal of Hematology & Oncology |
| title | A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China |
| title_full | A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China |
| title_fullStr | A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China |
| title_full_unstemmed | A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China |
| title_short | A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China |
| title_sort | homoharringtonine based induction regimen for the treatment of elderly patients with acute myeloid leukemia a single center experience from china |
| url | http://www.jhoonline.org/content/2/1/32 |
| work_keys_str_mv | AT huangchongmei ahomoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT chenli ahomoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT songxianmin ahomoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT yangjianmin ahomoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT lushuqing ahomoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT wangjianmin ahomoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT houjun ahomoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT zhangweiping ahomoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT huangchongmei homoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT chenli homoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT songxianmin homoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT yangjianmin homoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT lushuqing homoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT wangjianmin homoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT houjun homoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina AT zhangweiping homoharringtoninebasedinductionregimenforthetreatmentofelderlypatientswithacutemyeloidleukemiaasinglecenterexperiencefromchina |